

Republic of the Philippines Department of Health FOOD AND DRUG ADMINISTRATION



FDA ADVISORY No. 2018 - 148

1 8 APR 2018

TO:

GENERAL CONSUMING PUBLIC

SUBJECT:

<u>Dissemination of ASEAN Post-Marketing Alert System</u> (PMAS) Reports on Adulterated Cosmetic Products With the Reference Nos. HSA071413032018 and

HSA071513032018

The Food and Drug Administration (FDA) hereby issues this public health warning to inform the public of the ASEAN Post-Marketing Alert System (PMAS) reports on the following cosmetic product/s:

	BRAND / PRODUCT NAME	FINDINGS	Report Reference No.
1.	Wonderglow TM Whitening Specialist Super Ultra Glowing Cream a. Glowing Day Cream b. Glowing Night Cream c. Soap	Glowing Night Cream was verified to contain excessive amount of mercury (7,524 ppm)	HSA071413032018 ¹
2.	Tati Skin Care Therapy 1 Cream	Verified to contain excessive amount of mercury (48,267 ppm)	- HSA071513032018 ²
3.	Tati Skin Care Therapy 2 Cream	Verified to contain tretinoin and hydroquinone	- HSAU/1513032018 ⁻

^{1,2} Attached are copies of the Singapore PMAS Reports with Reference Nos. HSA071413032018 and HSA071513032018

The aforementioned products have been tested by the Health Sciences Authority of Singapore as part of its post-marketing surveillance activities and the results of the laboratory analyses show that the products are not compliant with the technical standards set forth by the ASEAN Cosmetic Directive (ACD).

Products #1 and #2 have been verified to contain mercury beyond the maximum allowed limit of 1 part per million (ppm). Mercury is a naturally occuring heavy metal which is known to be severely hazardous to health even in small amount. People exposed to mercury exhibits symptoms including but not limited to tremors, numbness and tingling in the hands and feet, gingivitis or inflammation of the gums, pink discolouration of the hands and feet especially in children, irritability, and photophobia or sensitivity to light. Nursing mothers are doubly vulnerable because mercury is passed on to nursing babies through breast milk which can affect the baby's development.



Product #3 has been found to contain hydroquinone and tretinoin, both of which are no longer allowed to be part of a cosmetic product and are classified as drug products in the Philippines because of its multiple serious adverse effects (i.e. sensitivity to light, skin redness and permanent skin discoloration) when used indiscriminately. Additionally, tretinoin may also cause harm to developing fetus. Women planning to get pregnant or are already expecting are strongly advised to avoid using products containing tretinoin.

Because of the hazards posed by the aforementioned cosmetic products, the public is strongly advised to be vigilant and report to FDA, through any of the following channels, any encounter with them:

1. Send an e-mail via report@fda.gov.ph;

- 2. Call the Center for Cosmetics Regulation and Research (CCRR) hotline (02) 857-1900 local 8113 or 8107; or
- 3. Utilize the agency's online reporting facility, eReport, at ww2.fda.gov.ph/ereport.

Furthermore, the public is also advised to only buy cosmetic products that have been notified with FDA. If unsure of a product's notification status, consumers may verify whether the product is authorized by FDA using the *Search* engine embedded in the FDA website which is accessible at www.fda.gov.ph. For more information and inquiries, please e-mail us at info@fda.gov.ph or call the CCRR hotline mentioned above.

Dissemination of the information to all concerned is requested.

NELA CHARADE G. PUNO, RPh

DTN 20180402084648

ASEAN POST-MARKETING ALERT SYSTEM (Form A) Tick √ 1. Level of confidentiality: (√) Adulteration () Cancellation of registration () Labelling revision () Counterfeit () Internal / Restricted circulation () Recall of product () Quality defect (√) On public domain, specify website: () Safety aspect () Suspension of registration (√) Withdrawal of product () Others, please specify: () Others, please specify: 4. Source / Type of signal: () Local ADR reports () Decision made by other regulatory authorities &/or industry () Scientific literature / local studies (√) Others, please specify: ($\sqrt{}$) Post-market sampling and testing activities Public feedback 5. Product type: () Biologic () Traditional medicine () Others, please specify: (√) Cosmetic () Health supplement () Pharmaceutical 6. Forensic classification in your () General sales list / () Prescription only country: Over-the-counter () Others, please specify: () Pharmacy only 8. Alternative name (e.g. local language): 7. Brand / Product name (or drug class): Wonderglow[™] WHITENING SPECIALIST SUPER ULTRA **GLOWING CREAM contains** - GLOWING DAY CREAM - GLOWING NIGHT CREAM - Soap 9. Active ingredient / Generic name / Full formula (for cosmetics, traditional medicines etc.): 'GLOWING NIGHT CREAM' was tested to contain mercury 7524 ppm (w/w) 10. Dosage form (if applicable): 11. Strength (if applicable): NA 12. Pack size / Presentation: 13. Batch / Lot number: 1 container x 20mg NA 15. Date manufactured (if applicable): 14. Expiry date (if applicable): 16. Intended use as listed on label: 17. Countries which the product is exported to: 18. Marketing authorisation holder / Product licence holder / Company responsible for placing product in the market:

19. Name & country of manufacturer

Wonder Glow Worldwide

Email: wonderglowcosmetics@yahoo.com

Website: www.wonderglowcosmetics.com & www.wonderglow465.blogspot.com

Hp: +60103130800 Mobile: +607721188

Details / Action(s) taken

20. Details of investigations e.g.

- 'Glowing Night Cream' was tested to contain mercury 7524 ppm (w/w)
- Investigation is ongoing.

21. Actions / proposed actions to be taken

- NA

Reporting country / authority	
22. Name of country / Issuing authority: Singapore / Health Sciences Authority	23. Report reference no.: HSA071413032018
24. Department / Designation of person issuing the alert: Vigilance and Compliance Branch	25. Date of report: 13 March 2018
Contact person	
26. Name: Dr Wint Maw Thinn	27. Department / Designation: Vigilance and Compliance Branch / Regulatory Specialist
28. Email address: Wint_maw_thinn@hsa.gov.sg	29. Contact no. Telephone no.: 63045463 Fax no.: 64789069

Indicate NA whenever the field is not applicable.

^{*} To provide photograph of product and press statement if any.













ASEAN POST-MARKETING ALERT SYSTEM (Form A) 3. Action: Tick V 2. Issue: () Cancellation of registration (V) Adulteration 1. Level of confidentiality: () Counterfeit () Labelling revision () Internal / Restricted circulation () Recall of product () Quality defect (V) On public domain, specify website: () Safety aspect () Suspension of registration (√) Withdrawal of product () Others, please specify: () Others, please specify: 4. Source / Type of signal: () Local ADR reports () Decision made by other regulatory authorities &/or industry () Scientific literature / local studies (√) Others, please specify: () Post-market sampling and testing Public feedback 5. Product type: () Traditional medicine () Biologic (V) Cosmetic () Others, please specify: () Health supplement () Pharmaceutical 6. Forensic classification in your () General sales list / () Prescription only country: Over-the-counter () Others, please specify: () Pharmacy only 7. Brand / Product name (or drug class): 8. Alternative name (e.g. local language): Tati skin care Therapy 1 cream and Tati skincare Tati skin care Therapy 2 cream 9. Active ingredient / Generic name / Full formula (for cosmetics, traditional medicines etc.): Tati skin care Therapy 1 cream - Mercury 48267 ppm(w/w) Tati skin care Therapy 2 cream - Tretinoin and Hydroquinone 10. Dosage form (if applicable): 11. Strength (if applicable): 12. Pack size / Presentation: 13. Batch / Lot number: 1 container x 5g or 1 container x 10g 14. Expiry date (if applicable): 15. Date manufactured (if applicable): 16. Intended use as listed on label: 17. Countries which the product is exported to: 18. Marketing authorisation holder / Product licence holder / Company responsible for placing product in the market: Tati_skincare NOT 170505953K / NOT 170505954K 19. Name & country of manufacturer www.tatiskincare.com

20 D-4-11		
Details of investigations e.g. Tati skin care therapy cream 1 found to contain Merc Tati skin care therapy cream 2 found to contain Treti Investigation is ongoing.		
21. Actions / proposed actions to be taken - NA		
Reporting country / authority		
22. Name of country / Issuing authority: Singapore / Health Sciences Authority	23. Report reference no.: HSA071513032018	
24. Department / Designation of person issuing the alert: Vigilance and Compliance Branch	25. Date of report: 13 March 2018	
Contact person		
26. Name: Dr Wint Maw Thinn	27. Department / Designation: Vigilance and Compliance Branch / Regulatory Specialist	
28. Email address: Wint_maw_thinn@hsa.gov.sg	29. Contact no. Telephone no.: 63045463	

Fax no.: 64789069

Indicate NA whenever the field is not applicable.

* To provide photograph of product and press statement if any.





